Advisors:• Professor Masad Damha,

Department of Chemistry,McGill University, Canada

• Dr Troels Koch, Vice President ofResearch, Santaris Pharma A/S,Denmark

• Dr Muthiah Manoharan, VP DrugDiscovery, AlnylamPharmaceuticals, USA

• Dr Michael McLean, ChiefExecutive Officer, McLean andMcLean Ltd., UK

• Dr Thomas Rupp, ProteinSeparations, GE Healthcare Bio-Sciences Europe GmbH,Germany

• Dr Yogesh S. Sanghvi, President,Rasayan Inc., USA

• Dr Brian Sproat, Chief ScientificOfficer, RNA-TEC, Belgium

• Dr Susan Srivatsa, President,ElixinPharma, USA

• Professor Cy Stein, Professor ofMedicine, Albert Einstein Collegeof Medicine, USA

Oligonucleotides, RNAi and Peptides for the DrugDevelopment and Manufacturing Industry

Informa Life Sciences 9th Annual Conference

2008

Media Partners:

Associate Sponsors:Corporate Sponsor:Afternoon Site Visit to Coley Pharmaceuticals1 December 2008

Conference: 2-3 December 2008Exhibition: 2-3 December 2008Start-up Day: 1 December 2008

Post-Workshops: 4 December 2008Location: Hilton Düsseldorf, Germany

NEW FOR

2008!!

Attend this exclusive opportunity to visit Coley Pharmaceutical GmbHin Düsseldorf.

Pre- Conference Symposium 1 December 2008

Keynote Plenary Presentations:

Reduced Pricefor Start-upand SmallBiotech!!

Post-Conference Symposium Y – 4 December 2008

NanoTIDES – Nanomaterials from Nucleotides and Peptides

• Professor Nadrian C. Seeman, New York University, USA• Professor Christof M. Niemeijer, University of Dortmund, Germany• Professor Guenter von Kiedrowski, University of Bochum, Germany• Professor Friedrich C. Simmel, Technical University of Munich, Germany• Professor Harm-Anton Klok, Ecole polytechnique, Fédérale de Lausanne Laboratoires des

polymèr, Switzerland• Professor Tanja Weil, National University of Singapore & Director of Chemical R&D,

Merz Pharmaceuticals GmbH, Germany• Dr Jeroen L.M. Cornelissen, Radboud University Nijmegen, The Netherlands• Professor Andreas Herrmann, Zernike Institue for Advanced Materials, The Netherlands

Tools for a Start- Up Company- How to Take a Product Through to Development

Register online: www.informa-ls.com/eurotides

Hear from and network with over50 expert leaders in the field

PLUS DON'T MISS....

Oligonucleotides in RNA Interference: Newdevelopments for application

Professor Fritz EcksteinMax-Plank-Institute forExperimental Medicine, Germany

Opportunities and challenges of developing peptide drugs in the pharmaceutical industry

Dr Waleed DanhoDistinguished Research Leader, Discovery ChemistryHoffmann-LaRoche Inc., USA

“20 years of oligonucleotide drugdevelopment - what do we have to show?”

Dr Arthur KriegChief Scientific OfficerPfizer, USA

Executive Sponsor:

Places are Limited so Book Early

Workshop W: Tools for a Start- Up Company- How to Take a Product Through to Development

08:45 Registration and Coffee

09:30 Chairperson’s Opening RemarksDr G. Susan Srivatsa, President, ElixinPharma, USA

09:35 Setting the business up – getting startedThe first steps in the creation of a new biotechnology company involve manydecisions which will be critical for the future of the company, such as in-licensing ofkey IP, arranging seed financing and demonstrating proof of concept. Thispresentation will seek to establish some of the “do’s and don’ts” for starting yourcompany on the right path.Dr Michael J. McLean, CEO, McLean and McLean Ltd, UK

10:10 Morning Tea and Coffee

10:45 Quality assurance - Considerations for start-up’sIt is important for a start up company to introduce quality assurance into theirprogrammes, organisation and culture from the earliest opportunity. The challengesare how to determine what is appropriate Quality Assurance for each developmentphase and how to structure a Quality Management System that can expand as yourproduct progresses through the development cycle. This session will provide someexpert guidance on Phase Appropriate Quality Management as a tool for businesssuccess.Gillian Sandilands, Senior Director Global GXP Training, SolvayPharmaceuticals, The Netherlands

11:25 Effective CMC development in a virtual environmentDevelopment of peptide or oligonucleotide therapeutics in a start-up environment

poses special challenges. Awareness of the evolving regulatoryexpectations in various regions is important for regulatory andcommercial success. This presentation will provide strategies toeffectively meet the CMC requirements while supporting preclinical andclinical studies in a virtual/semi-virtual start-up environment.Dr G. Susan Srivatsa, President, ElixinPharma, USA

12:00 Lunch

13:30 IP rights: Getting off on the right footIP rights are a two-edged sword. Although seen as potential constraints on freedomto operate, at the same time they are an essential credibility factor for talking topotential investors and key negotiating chips in licensing third party technology in orlicensing your own technology out. But whatever use you want to make of them, it isvital to understand how they work in order to do a deal you can live with.Lorna Brazell, Partner, Bird and Bird, UK

14:05 Regulatory challenges of a small companySmall biotech companies face a different set of challenges compared to “bigpharma”, starting with the way on how to gather regulatory intelligence and notending with a development plan, which not only leads to an approval but also“survives” a potential due diligence by either VC and/or potential pharma partnersDr Stefan Blesse, Principal Consultant, Granzer Regulatory Consulting &Services, Germany

14:40 Afternoon Coffee break and Registration for the Site Visit

Afternoon Site Visit to Coley Pharmaceuticals

Attend this exclusive opportunity to visit Coley Pharmaceutical GmbH inDüsseldorf. Coley is Pfizer’s centre for nucleic acid chemistry andimmunology, working closely together with Pfizer’s RNAi research centerin Cambridge, MA in developing therapeutic applications of RNAi to meetpatients’ needs.

M O N D A Y 1 D E C E M B E R 2 0 0 8

Sponsorship and Exhibition Opportunities Access Industry Decision Makers

EuroTIDES 2008 conference and exhibition provides an ideal opportunity to gain exposure for your products and services, to all of those involved with the Oligonuleotide, RNAi and PeptideManufacturing and Drug Development Industry. With a number of lead generating, networking and branding opportunities available, you will be able to access senior level decision makersacross Europe, USA and Asia. To find out more on the sponsorship and exhibition opportunities, please contact: lily.chong@informa.com or tel: +44(0)207 017 5011

EuroTIDES 2008 Exhibition 2-3 December 2008

Corporate Sponsor Girindus is a technology driven company offering thepharmaceutical, biotech and cosmetic industries a partnerfor clinical scale and commercial scale synthesis ofoligonucleotides. Girindus operates a cGMP compliant(FDA inspected) facility in Cincinnati, Ohio. The facility is

fully staffed and equipped for solid phase synthesis of oligonucleotides (multiplesynthesizers up to 120 mmol capacity, ion exchange and reverse phase chromatographyand multiple lyophilyzers capable of 3 kg batch sizes). The oligonucleotide group alsoperforms process development and optimization of solid phase synthetic routes yieldingefficient processes with freedom to operate from IP restrictions. Analytical capabilitiesinclude HPLC, GC, HPLC/MS, GC.MS, NMR (300 mHz), CGE, KF, and endotoxindetermination. Associated offerings include GMP radiolabeling, ICH compliant stabilitystudies and analytical method development and validation.

Executive Sponsor

Avecia OligoMedicines is a world leading contractservices organization committed to setting newstandards in the development, manufacture andanalysis of therapeutic oligonucleotide APIs. Havingmanufactured over 1000 different sequences, we have

experience with all types of oligonucleotide classes including siRNAs, aptamers,chimeras, molecular decoys and DNA. We have performed process validation formultiple oligonucleotides and our FDA-registered facility, located in the US just outsideof Boston, has manufacturing capability to produce API for the pre-clinical, clinical, andlaunched product markets. Our installed production capacity is able to produceoligonucleotide volumes that range from single grams up to 100s of kilograms. AveciaOligoMedicines is a customer-focused organization that strives to build value for alloligonucleotide API developers as they progress through the clinic, and beyond.

Associate SponsorsColey Pharmaceutical GmbH in Düsseldorf, Germany was acquired in2007 as part of Pfizer’s commitment to invest in RNAi andoligodeoxynucleotide therapies. Coley is Pfizer’s center for nucleic acid

chemistry and immunology, working closely together with Pfizer’s RNAi research center in Cambridge,MA in developing therapeutic applications of RNAi to meet patients’ needs

As the oligonucleotide market continues to grow, ChemGenes remainscommitted to introducing novel products, while maintaining our existingproduct mix. With over 25 years of experience in phosphoramidite &nucleoside chemistry, our custom synthesis capabilities are unmatched.

All of us at ChemGenes are devoted to providing you with invaluable customer service andcomprehensive technical assistance.

Conference Padfolio Sponsor American International Chemical’s Advanced Technology Division is dedicatedto the expanding fields of Oligonucleotide chemistries.AIC is a leader in the Activator market offering 5-Ethylthio-1H-tetrazole, 5-Benzylmercaptotetrazole and licensed 4,5-Dicyanoimidazole. AIC also offers a wide

variety of DNA and RNA synthesis reagents including: Specialty Phosphoramidites, Custom MoleculeSynthesis, and Sulfurizing Reagents.

Technology Tutorial SponsorEurogentec is a leading supplier for genomic and proteomic research,specialising in oligonucleotide synthesis, oligos for In vitro Diagnostic,

custom antibody production, as well as qPCR reagents, microRNA, siRNA, peptides, DNA Array andmolecular biology consumables. «Eurogentec Biologics» department is a full-service ContractManufacturing Organisation (CMO) delivering research, development and production services for cGMPclinical batch manufacturing.

Featured Exhibitors

Approximate Times (this may vary)15:00 Leave Hotel 15:30 Arrive for Presentations and

Discussions16:40 Laboratory Tour of Groups18:00 Pick up to Hotel

Places are Limited

so BookEarly

AdditionalBookable

Day

Plenary Session and Keynote

E U R O T I D E S C O N F E R E N C E D A Y O N E • T U E S D A Y 2 D E C E M B E R 2 0 0 8

11:30 Recent advancements in the preparative purification of aptamersAptamers are often conjugated to large polyethylene glycol (PEG) moieties to create anapparently larger molecule that will be resistant to renal filtration and clearance, therebyincreasing the aptamer’s circulation half life. Due to the high degree of complexity of theoligonucleotide-PEG conjugate they are often difficult to analyse and purify by standardmethods. Recent advancements that aid in the purification and isolation of PEGylatedaptamers will be presented.Dr Paul J. Hatala, Senior Scientist, Archemix Corp, USA

Spotlight Presentation12:00 The integration of statistics tools and high-throughput analysis techniques

in oligonucleotide API development and manufactureThe challenges of demonstrating reproducibility from batch to batch and thedemonstration of process understanding on the scale-up from lab to plant are not to beunderestimated. This presentation will examine via case study the use of multivariatestatistical analysis, high throughput LCMS and process analytical technology tools inoligonucleotide API development and manufactureDr Paul McCormac, Director of Process Development, Avecia OligoMedicine, USA

12:30 Impact of sequence diversity on large scale manufacturing of RNA-basedtherapeuticsIn this presentation, the manufacturing challenges derived from the diversified sequencesof the synthesized oligoribonucleotides will be discussed in the context of large scalemanufacturing of RNA-based therapeutics. Several examples will be presented with thegoal of developing a robust approach to optimisation of the manufacturing process.Dr Tadeusz K. Wyrzykiewicz, Section Head of Oligonucleotide Group, GirindusAmerica, USA

13:00 These sessions are hosted by leading companies who operate in the field of EuroTIDESand offer an opportunity to learn about the latest developments in the industry. If youwould like to host a tutorial please contact lily.chong@informa.com

13:30 Lunch and Poster/Exhibition Viewing Time

14:30 These sessions are hosted by leading companies who operate in the field of EuroTIDESand offer an opportunity to learn about the latest developments in the industry. If youwould like to host a tutorial please contact lily.chong@informa.com

15:00 Low-cost industrial chemo-enzymatic synthesis of oligopeptides and C-terminal thioesters and arylamides thereofIn chemo-enzymatic peptide synthesis, the peptidic bonds are formed by enzymes(usually proteases) and optionally the N- and/or C-(de)protection is also performedenzymatically. Important advantages over chemical peptide synthesis are that no side-chain protection is required and that no racemisation occurs rendering purification morecost-efficient.Dr Quirinus B. Broxterman, DSM Pharmaceutical Products - Innovative Synthesis &Catalysis (DPP-ISC), DSM, The Netherlands

15:30 How does chemistry make nucleic acids more potent, useful andaffordable?Here we present synthesis, characterisation and application of RNA and DNA mimetics –oligonucleotide N3’®P5’-(thio)-phosphoramidates with 2’-OH or 2’-F substitutions, aswell as their lipid conjugates. A covalent conjugation to various lipid groups at severalsites of these molecules (either at 5’-, or 3’- termini, or nucleoside bases) was introducedto improve their bio-availability and modulate pharmacokinetic parameters in vivo. Dr Sergei M. Gryaznov, Director and Senior Research Fellow, Geron Corporation,USA

16:00 Afternoon Tea and Coffee with Exhibition/Poster Viewing Time sponsored by:

16:30 Recent advances with 2'-Cpep RNA chemistry: A cost effective approach forRNA amidites Among various raw materials required for the synthesis of RNA, the amidite building-blocks contribute the largest share of the cost. In this presentation, we will describe ourefforts in manufacturing affordable 2'-Cpep RNA amidites and their use in the synthesisof RNA.Dr Yogesh Sanghvi, President, Rasayan Inc

17:00 Process development for large scale manufacturing of peptide APIsModern industrial manufacturing of peptide APIs requires highly developed processes,consistently delivering the regulatory expectations towards product quality and processcontrol. Process development starts with the proof of concept of a proposed route, goesthrough process optimisation and process qualification phases, and finally ends in thedesign of an industrial manufacturing concept and in the validation of the process.Dr Oleg Werbitzky, Director Innovation, Lonza, Switzerland

17:30 End of Day One followed by Drinks Reception in the Exhibition Hall

TRACK 2: Challenges with Manufacturing and RegulatoryChallenges for Oligonucleotides and Peptides

11:30 Immune activation by DNA and RNA, implications for hybridization-basedoligo(ribo)nucleotide therapiesSingle- or double-stranded RNA containing defined sequence motifs or modificationsactivate TLR7/8- or RIG-I-mediated immune responses. TLR-induced immune activationprovides a transient but broad spectrum defense against many pathogen challenges andresults in anti-tumor activity. These immune stimulatory effects may be employed in specificdisease indications, but cause unwanted toxicities in other applications, such as RNAi.Dr Jörg Vollmer, Vice President Discovery & Development, Coley Pharmaceutical (APfizer Company), Germany

12:00 Self-inactivation of HIV by its own RT/RNase HWe have designed a method to inactivate HIV infectivity in the extracellular environmentby activating the virion-associated Ribonuclease H. We compared the effects of the hairpin-loop-structured DNA to antisense DNA and siRNA and find clear differences. Themechanism of uptake is independent of TLR9 and not yet understood.Professor Karin Moelling, Institute of Medical Virology, University of Zurich,Switzerland

12:30 UNA (Unlocked Nucleic Acid) – A tool for improved RNAi applicationsResults from cell culture and in vivo studies will be reported to document that UNAmonomers are remarkably useful as novel constituents of siRNA duplexes. UNA monomersthus induce improved potency and reduced off-target effects relative to unmodified siRNAduplexes.Professor Jesper Wengel, Nucleic Acid Centre, University of Southern Denmark

13:00 Spotlight PresentationThese sessions are hosted by leading companies who operate in the field of EuroTIDES andoffer an opportunity to learn about the latest developments in the industry. If you wouldlike to host a tutorial please contact lily.chong@informa.com

13:30 Lunch and Exhibition/Poster Viewing Time

14:30 Towards PNA and Peptide-PNA conjugates as therapeuticsWe have selected serum-stabilised PNA internalisation peptides (Pip) which whenconjugated to a 18-mer PNA result in splice correction activity at sub µM concentrations inthe absence of any transfection agent in a HeLa pLuc705 splice correction model. Such Pip-PNA conjugates are being applied to a mouse mdx model of Duchenne muscular dystrophywith promising exon skipping activity in vivo.Dr Michael J Gait, Laboratory of Molecular Biology, Medical Research Council, UK

15:00 Carbohydrate solid phase synthesis – An opportunity for nucleic acidtargeting?Rapid access to synthetic oligosaccharides using methods that resemble those employedfor the preparation of peptides and oligonucleotides allows us to explore carbohydrates astargeting devices. Described is an integrated platform that relies on synthesis, screeningand imaging to discover new carbohydrate receptors and their potential to deliver othermolecules selectively into cells.Professor Peter H. Seeberger, Laboratory for Organic Chemistry, Swiss FederalInstitute of Technology (ETH) Zurich, Switzerland

15:30 Combinatorial approaches for the design of antiviral drugs: RNA as a targetIWe developed aptamers against crucial RNA structures of HIV-1 and HCV genomes thatreduce viral multiplication in cultured cells. Using a genetic suppressor element strategy weidentified a sequence encoding a regulator of the HCV internal ribosome entry site thatshows a specific effect on either bicistronic reporter, replicon or HCV RNAs in Huh7 cells.Professor Jean-Jacques Toulmé, Directeur Institut Européen de Chimie et Biologie,Université de Bordeaux, France

16:00 Afternoon Tea and Coffee with Exhibition/Poster Viewing Time sponsored by:

16:30 Peptides tailored to interfere with protein interaction and functionWe use semi-rational design in combination with selection systems to generate peptidesinterfering with pathogenic protein-protein interaction. A protein-fragmentcomplementation assay (PCA) in combination with a 'Competitive and Negative DesignInitiative' (CANDI) was developed for the screening and selection of specific inhibitors withhigh stability and specificity. Different strategies will be discussed for targeting theoncoproteins Myc, Jun, Fos and AF10 using tailored D- and L-peptides.Dr Katja M. Arndt, Department of Biology, University of Freiburg, Germany

17:00 Combination approaches to inhibit ongoing coxsackievirus B3 infection inhuman myocardial fibroblast cell lineWe established a model with a persistently CVB-3 infected human myocardial fibroblastcell line and found our RNAi-approach still to be suitable to reduce the virus titre.Interestingly, however, when we combined a soluble variant to the virus receptor (sCAR)and siRNAs we observed a strong synergistic effect of the two strategies, since sCARprevents cellular entry of CVB-3, while RNAi destroys viral RNA intracellularly.Professor Jens Kurreck, Group Leader, Institute for Chemistry, University ofStuttgart, Germany

17:30 End of Day One followed by Drinks Reception in the Exhibition Hall

TRACK 1: Research and Development of Oligonucleotidesand Peptides

09:00 Registration and Morning Coffee09:05 “20 years of oligonucleotide drug development - what do we have to show?”

The era of antisense drug development began with a bang about 20 years ago, and hassince endured several swings of the pendulum between delirious excitement and investorcynicism. Originally seen as unwanted antisense side effects, aptamers and immunestimulatory oligodeoxynucleotides have shown great promise on their own as drugcandidates, advancing close to approval in several indications. More recently RNAi hasrejuvenated investor excitement in the therapeutic potential of gene-specificoligonucleotides, but the lack of safe and effective delivery has hindered clinicaldevelopment so far.Dr Arthur Krieg, Chief Scientific Officer, Pfizer, USA

09:45 Opportunities and challenges of developing peptide drugs in thepharmaceutical industryThe peptide market is growing nearly twice as fast as that for all other types ofpharmaceuticals due to the increased number of therapeutic targets and improved deliverymethodologies. There are 67 therapeutic peptides on the market, 150 in clinical phases and400 in preclinical stages. The market size for 2007 is estimated to be 3.01 billion US$. The

important factors requiring considerations before starting peptide-based projects, includingde-risking strategies, unmet medical needs, the competitive landscape and COG, areanalysed in this presentation.Dr Waleed Danho, Distinguished Research Leader, Discovery Chemistry, Hoffmann-LaRoche Inc., USA

10:20 Oligonucleotides in RNA Interference: New developments for application.The importance of siRNAs for the inhibition of gene expression has continued to be agrowing field. For the analysis of gene functional analysis they are most attractive. Inaddition the application for combatting diseases makes great progress. The interest insiRNAs has been joined by that for the microRNAs. Their use for application in a therapeuticmanner is at present limited to their knock-down by antagomirs and the like. The reviewwill summarise particularly progress in the application area with an emphasis for methodsand ideas for cell- and organ-specific delivery.Professor Fritz Eckstein, Max-Plank-Institute for Experimental Medicine,Germany

10:55 Morning Tea, Coffee and Exhibition/Poster Viewing Time sponsored by:

D A Y T W O • W E D N E S D A Y 3 D E C E M B E R 2 0 0 8

08:30 Morning Tea and Coffee

09:00 Chairperson’s Opening Remarks

09:05 European regulatory perspective on oligonucleotides and peptidesThis presentation will provide an overview about the regulatory landscape foroligonucleotides and peptides. Changes in regulation and their influence on these substanceclasses will be discussed. Issues related to the pharmaceutical quality of oligonucleotides andpeptides are highlighted.Dr René Thürmer, Pharmaceutical Expert, Unit Pharmaceutical Biotechnology, BfArM –Federal Institute for Drugs and Medical Devices, Germany

09:35 Update on the review of oligonucleotide products by regulatory agencies: Anindustry perspectiveThis presentation provides a historical overview and evolution of the US, European and otherregulatory agencies’ review practices of oligonucleotide products. Also highlighted areemerging trends in the industry to meet current expectations for the characterisation andquality control of oligonucleotide drug candidates entering clinical development.Dr Susan Srivatsa, President, ElixinPharma, USA

10:05 Morning Tea, Coffee and Exhibition/Poster Viewing Time sponsored by:

10:45 Evaluation of the impact of the variables related to thermal melt temperaturedetermination by UV spectroscopyThe melting temperature depends on both the length and the nucleotide sequence, but canbe impacted by several measurement technique variables. By understanding the variablesaffecting Tm determination and controlling them, more accurate Tm values can result. Thispaper investigates the impact of the variables related to this technique on the accuratedetermination of thermal melt.Dr Judy Carmody, President, Avatar Pharmaceutical Services, USA

11:15 The role of analytical chemistry in oligonucleotide process developmentAnalytical techniques that facilitate oligonucleotide drug substance yield and purityimprovements will be presented. The impact that analytical chemistry has on drug productformulation activities will be described.Dr Daniel Capaldi, Vice President, Analytical and Process Development, IsisPharmaceuticals, Inc., USA

11:45 Analysis of peptides in GMP environmentsMeasurements of the racemate content, the content of amino acids and water as well asthose of remaining solvents and counter ions are of particular importance when it comes todetermining the purity of peptidic products. Especially in GMP environments, certain physicaland chemical properties of peptides need to be considered when doing these analyses.Several issues related to this challenge will be highlighted.Dr Juergen Gerhardt, CEO, C.A.T. GmbH & Co KG, Germany

12:15 Spotlight PresentationThese sessions are hosted by leading companies who operate in the field of EuroTIDES andoffer an opportunity to learn about the latest developments in the industry. If you would liketo host a tutorial please contact lily.chong@informa.com

12:45 Lunch and Exhibition/ Poster Viewing Time

14:00 Liposomal carriers of oligonucleotides: Dynamic Shape Theory guides efficacyand provides a rational for screening and optimisationThe underlying Dynamic Shape Theory (DST) is taking into account pH dependent shapechanges, lipid-lipid salt formations and counterion binding to predict the fusogenic state of alipid membrane. DST facilitates the in silico screening of large lipid libraries and provides arational for the practical selection and optimization of lipid carriers.Dr Steffen Panzner, CSO and Founder, Novosom AG, Germany

14:30 Delivery opportunities and challenges on the pathway to siRNA therapeuticsDicer constructs and modifications provide highly effective siRNAs; however, ultimate activityrequires efficient delivery. We are developing novel lipids to reduce toxicity and enableattachment for targeting entities, and peptides for maximizing siRNA payload, intracellularescape, or cell specificity; all of which are proving essential for developing therapeutic siRNAs.Dr Michael V. Templin, Vice President, Discovery Research and PharmaceuticalDevelopment, MDRNA Inc., USA

15:00 Afternoon Tea and Coffee with Exhibition/Poster Viewing Time sponsored by:

15:30 Delivering RNAi therapeutics using chemistryDr Muthiah Manoharan, VP Drug Discovery, Alnylam Pharmaceuticals, USA

16:00 Preclinical pharmacology of a SNALP delivered siRNA-based therapy for cancerand metabolic diseaseWhen siRNA are encapsulated in stable nucleic acid lipid particles (SNALP) and administeredby intravenous injection to mice, rats or monkeys a single treatment results in dose-dependent silencing of target mRNA expression in the liver, liver tumours, or distal tumourmetastasis, typically yielding significant pharmacological effects that manifest as early as onehour after administration and may last as long as weeks.Dr Ian MacLachlan, Chief Scientific Officer, Tekmira Pharmaceuticals Inc, Canada

16:30 Cellular and intracellular delivery of functional siRNA: A quantitative view onnew biology and systems to study major technical hurdlesThe phosphorothioate(PTO)-stimulated cellular uptake of siRNA represents a novel option fordelivery and for bypassing off-target effects as it makes use of the caveosomal rather thanthe endosomal vesicular transport system in human cells. This new biology and technologiesto deeper and quantitatively investigate cellular delivery and intracellular trafficking of siRNAwill be summarised.Professor Georg Sczakiel, Institut für Molekulare Medizin, Universität zu Lübeck,Germany

17:00 End of Conference

Challenges and Strategies for Peptide and Oligonucleotide Delivery

TRACK 2: Regulatory and Analytical Strategies ofOligonucleotides and Peptides

08:30 Morning Tea and Coffee

09:00 Chairperson’s Opening Remarks

09:05 Antisense oligonucleotide GED-0301 against Smad7 for the oraltreatment of Crohn’s diseaseWe are developing a novel oligonucleotide-based therapeutic approach for themanagement of active Crohn’s disease. The compound is named GED-0301 andtargets Smad7. We designed and developed an oral dosage form of GED-0301 todeliver the compound in the small intestine and right colon and obtain a “topical”effect of the drug.Dr Francesca Viti, Project Manager, Pharma Division, Giuliani S.p.A., Italy

09:35 Locked Nucleic Acid: New concepts for single stranded RNA InhibitionSingle stranded LNA antagonists can be used as expression inhibitors of mRNA andmicroRNA and thus, LNA constitutes a common platform for potent inhibition ofcoding and non-coding RNA. The pharmacology of LNA will be illustrated in thepresentation - exemplified with rodent and non-human primate data. Finally, thecellular up-take and the intracellular mechanism of action will be discussed.Dr Troels Koch, Vice President Research, Santaris Pharma A/S, Denmark

10:05 Morning Tea, Coffee and Exhibition/Poster Viewing Time sponsored by:

10:45 Development of Atu027, an siRNA-lipoplex targeting PKN3 expression,for therapy in oncologyWe have established the AtuPLEX, a liposomal siRNA formulation, for RNAi-mediated suppression of gene expression in the vasculature. This strategy forinhibition of PKN3 expression (Atu027) is currently being developed for therapeuticapplication in oncology. In preparation of the upcoming phase I clinical trial, we willdiscuss Atu027 current status with regard to RNAi function, efficacy, PK andtoxicology.Dr Jörg Kaufmann, Senior Director Technologies, Silence Therapeutics AG,Germany

11:15 AL-108: Case study for an intranasal peptide in Alzheimer’s diseaseAL-108 is a cognitive and neuroprotective peptide currently in clinical developmentfor Alzheimer’s disease and cognitive-impairment in schizophrenia. The mechanismof action appears to involve stabilisation of microtubules, which are important forboth the structure and function of neurons.Dr Bruce Morimoto, VP, Drug Development, Allon Therapeutics, Canada

11:45 Development of a novel RNAi therapeutics platformDr Pamela A. Pavco, Vice President Pharmaceutical Development, RXiPharmaceuticals, USA

12:15 Spotlight PresentationThese sessions are hosted by leading companies who operate in the field ofEuroTIDES and offer an opportunity to learn about the latest developments in theindustry. If you would like to host a tutorial please contact lily.chong@informa.com

12:45 Lunch and Exhibition/ Poster Viewing Time

14:00 MicroRNA manipulation as a therapeutic strategy for cardiovasculardiseaseRecent studies have demonstrated the fundamental importance of microRNAperturbations in several forms of cardiovascular disease. By correcting microRNAlevels we hope to develop breakthrough therapies that target the fundamentalpathways responsible for this progressive, fatal condition.Dr William S. Marshall, President and CEO, Miragen Therapeutics, Inc., USA

14:30 LNA oligonucleotides as RNA antagonists for the control of cancer The utility of LNA-ONs directed against hypoxia inducible factor 1a (HIF-1a) andepidermal growth factor receptor 3 (ErbB3) as cancer therapeutics will be described.Preclinical and clinical data will be presented. Application of LNA-ON as cancertherapeutics may allow down regulation of critical targets that control tumor growthand have previously been considered “undruggable”.Dr Lee Greenberger, Vice President, Research, Enzon Pharmaceuticals, Inc.,USA

15:00 Afternoon Tea and Coffee with Exhibition/Poster Viewing Time sponsored by:

15:30 Preclinical development of the anti-CCL2 Spiegelmer NOX-E36Dr Sven Klussmann, Chief Scientific Officer, NOXXON Pharma AG, Germany

16:00 Antiviral MonoLex aptamersAnti-vaccinia and anti-influenza aptamers are selected from a combinatory ssDNAlibrary using a single-round approach of affinity chromatography and subsequentslicing of the column to obtain the binders. Such antiviral aptamers can be leads inthe development of active agents and binders in highly sensitive analytical assays.Dr Andreas Kage, Department of laboratory medicine, Charité -Universitätsmedizin Berlin & CSO and Co-Founder, AptaRes AG,Mittenwalde, Germany

16:30 End of Conference

TRACK 1: Pre-Clinical and Clinical Development ofOligonucleotides and Peptides

Post-Conference Symposium Y Thursday 4 December 2008

Registration: 09:30 Start: 10:00 End: 17:00 Lunch and Morning and Afternoon Tea Breaks Included

HIGH SPEED NETWORKINGTuesday 2 December 2008 at 16:00 (During afternoon tea break)

• With HIGH SPEED NETWORKING you can make more new business contacts inone session than most people will make in 6 months!

• Network with other professionals, one on one, a few minutes at a time• Leave with a pocket full of business cards and a

ton of new business connections!• Chances are you'll meet lots of people you wish

you had more time with. At the end of the firstday of the conference, continue networking atthe drinks reception in the exhibition hall

Registration will be on Tuesday 2 December 2008during the first break of the conference

Present a Poster at the ConferenceWould you like to share your research with your peers and the key industryleaders? Posters must relate to the congress theme and should illustrate novelscience, technologies and supporting data.

You must be booked on as a delegate to be able to present a poster.

To apply please email Louisa Maitland at: louisa.maitland@informa.com andsubmit your abstract of 200 words or less, written in English, listing the principleauthor and completing all the contact details (organisation, mailing address,E-mail, phone, fax, poster, title, additional authors).

Last date for submission of poster is 5th November 2008.

In order to secure the Poster Board, a fee of £99 will be required (Academics arefree).

DNA: Not merely the secret of lifeRobust devices have been built that are predicated both onstructural transitions and on hybridisation topology. 1D, 2Dand 3D lattices have also been assembled, which has led tocontrol over the geometrical structure of matter basedsolely on the design of DNA sequences.Professor Nadrian C. Seeman, Department ofChemistry, New York University, USA

Nanobiotechnology - Harnessing natural buildingblocks for novel applicationsDNA oligomers are powerful building blocks for thebiomimetic “bottom-up” assembly of superstructures andfunctional biomaterials. Our work is focussed on the DNA-fictionalisation of proteins and nanoparticles. The resultingconjugates can be used for biosensing, the decoration ofplanar surfaces, and the assembly of switchablenanomaterials and biocatalysts.Professor Christof M. Niemeijer, Department ofChemistry, Biochemical Microsystems, University ofDortmund, Germany

Nanostructures and the origin of lifeDuring the talk the link between the origin of life andnanotechnology will be discussed. We report on the usageof trisoligonucleotides for the noncovalent construction ofnanoobjects and copying of connectivity information withinthem. Finally, examples of surface-promoted replication andexponential amplification of DNA analogues will bepresented.Professor Guenter von Kiedrowski, Institute for

Organic Chemistry I, University of Bochum, GermanyThermodynamic aspects of DNA assemblyThe unique molecular recognition properties of DNA can beutilised for the assembly of supramolecular nanostructures.Two different paradigms – assembly with symmetrised DNAsequences and DNA origami – are studied with respect tothe thermodynamics and kinetics of the assembly process. Inparticular, a novel isothermal annealing procedure isintroduced which is based on denaturing agents.Professor Friedrich C. Simmel, Department of Physics,Technical University of Munich, Germany

Programmable nanoobjects of nucleic acids andsynthetic polymers for biomedicine anddiagnosticsWe developed several routes for the generation of hybridmaterials consisting of nucleic acids and synthetic polymersthat rely on chemical synthesis and methods from molecularbiology. The DNA-polymer conjugates self-assemble intowell defined nanoscopic objects that can be used forfluorescent and electrical DNA detection as well as drugdeliveryProfessor Andreas Herrmann, Department of PolymerChemistry and Bioengineering, Zernike Institue forAdvanced Materials, The Netherlands

Biohybrid Nanomedicines and self-assemblingbiomaterialsThis presentation will discuss the design and synthesis aswell as the results of an in-vitro proof-of-concept study of afamily of poly(ethylene glycol) (PEG) – coiled coil peptide

conjugates that are designed to competitively inhibit ordisrupt coiled coil oligomerisation processes that are relatedto human disease.Professor Harm-Anton Klok, Institute of Materials,Ecole polytechnique, Fédérale de LausanneLaboratoires des polymèr, Switzerland

Artificial and chemically modified proteins asfunctional nanocarriersThe introduction of functional groups into the scaffold ofalbumins facilitated the discovery of efficient gene deliverydevices. Artificial amino acids at distinct locations within theprotein RNAse offer the unique opportunity to switch theproteolytic activity upon the induction of external stimuli.Professor Tanja Weil, Department of Chemistry,National University of Singapore & Director ofChemical R&D, Merz Pharmaceuticals GmbH, Germany

Functional assembly of virus capsid peptidesThe coat protein of the Cowpea Chlorotic Mottle Virus self-assembles into virus-like spherical cages as a function of pHand salt concentration. This reversible process can be usedto include functional materials or catalysts, resulting in well-defined nanometer sized reactors of which the propertiescan be finely tuned.Dr Jeroen L.M. Cornelissen, Cluster for MolecularChemistry, Radboud University Nijmegen, TheNetherlands

Outline of the Day:With the advent of nanotechnology many efforts have been undertaken to make use of nanomaterials in medicine. Besides investigating issues related to toxicity and environmental impact ofnanoscale structures they found widespread applications for drug delivery and diagnostics. In mid 2006, the journal Nature Materials estimated that 130 nanotech-based drugs and deliverysystems were being developed worldwide. A lot of nanoscopic systems in regard to biomedicine are composed either of inorganic materials like quantum dots or constitute of polymeric orliposomal systems. However, recent developments show that nucleotides or peptides that are the central topic of Eurotides 2008 gain importance for the construction of novel nanomaterials.This is related to their programmable self-assembly. DNA with its self recognition properties has been found widespread applications for the construction of very well defined 2D- and 3Dnanostructures. The same holds true for peptides where certain motifs are used to create very precise aggregates in the nanometer regime. Both types of structures could be furtherfunctionalised with other materials to make multifunctional objects or arrays on the nanoscale. Finally it could be demonstrated that such materials have potential applications in the field ofbiomedicine regarding therapy, delivery and diagnostics. With the session “Nanomaterials from nucleic acids and peptides” we would like to highlight that development and bring it to theattention of academics and companies working in the area of nucleic acid and peptide based therapies.

Nanotides – Nanomaterials from Nucleotides and Peptides

Post-Conference Workshop Z Thursday 4 December 2008

Registration: 09:30 Start: 10:00 End: 17:00 Lunch and Morning and Afternoon Tea Breaks Included

The workshop will cover all aspects of RNA synthesis on solid-phase using commercially available reagents and will also cover some of the newer developments in RNA synthesis. Deprotectionmethods and tips on precautions will be discussed as well as the choice of purification methods depending upon the application foreseen for the particular product. The workshop will alsocover the synthesis of conjugates with peptides, proteins and PEG. Delegates will gain in depth knowledge of what is involved in the chemical manufacture of siRNA and aptamers and how toavoid potential pitfalls when dealing with substances as sensitive as RNA.

Manufacturing siRNA, aptamers and their conjugates

Session 1:Synthesis chemistry• Synthesis strategies and choice of protecting groups, old

& new: the pros and cons of TBDMS, TOM, ACE and morerecent 2´-OH blocking groups; choice of supports andactivator

• Introducing chemical modifications: e.g.phosphorothioates, 2’-O-methyls, 2’-fluoros, LNA, dyes,linkers, lipophilic groups, etc.

• Synthesis of conjugates with peptides, proteins or PEG forexample

Session 2:Deprotection and purification strategies• Deprotection schemes according to the choice of 2´-OH

protecting group used• Purification by HPLC: anion-exchange and reversed phase• Purification by gel filtration• Desalting methods: precipitation, gel filtration and

ultrafiltration• Potential pitfalls and how to avoid them

Session 3:

Analytical methods and quality control• Analytical anion-exchange HPLC• Reversed phase HPLC• Ion-pair reversed phase HPLC• Capillary gel electrophoresis• Size exclusion chromatography• Mass spectroscopy, LC-MS and impurity profiles• Endotoxin control

Workshop Leader: Dr Brian Sproat, CSO, Integrated DNA Technologies, BVBA and Managing Director, ChemConsilium GCV, Belgium

Pass Code Book Before 5 Sept 2008

4 DAY PASS: conference, start-up & postw/shop plus site visit CQ3364CXY/Z ❑ 1699 + VAT @19%

= £2021.81

3 DAY PASS: conference, start-up, site visitor post w/shop CQ3364CX/Y/Z ❑ 1399 + VAT @ 19%

= £1664.81

❑ 1099 + VAT @ 19% = 1307.812 DAY PASS: conference only CQ3364C

EuroTIDES 20081-4 December 2008Hilton Düsseldorf, Germany www.informa-ls.com/eurotides

5 Easy ways to Register

LP/L

M/L

C/CH

/TR

Conference Code: CQ3364CStart-Up Symposium: CQ3364XPost-Conf Symposium: CQ3364YPost-Conf W/Shop: CQ3364Z

+44(0) 20 7017 7481

+44 (0) 20 7017 7823

registrations@informa-ls.com

The Bookings DepartmentInforma UK LtdP O Box 406ByfleetKT14 6WL

Group Bookings: To take advantage of group bookings pleasecontact Simon Lau, Tel: +44(0)207 017 7165email simon.lau@informa.com

Your VIP number is on the address label. If there is no label, please quote

Terms and ConditionsFEE: This includes all technical sessions, lunch and documentation.CANCELLATIONS: Cancellations received in writing before and on 17November 2008 will be subject to a service charge of £99. The full conferencefees remain payable after 17 November 2008. Substitutions are welcome at anytime.It may be necessary for reasons beyond the control of the organiser to alter thecontent and timing of the programme or the identity of the speakers. In theunfortunate event that an event is cancelled Informa are not liable for any costsincurred by delegates in connection with their attendance. This contract issubject to English Law.

ARE YOU REGISTERED?: You will always receive an acknowledgement ofyour booking. If you do not receive anything, please call us on +44(0) 20 7017 7481 to make sure we have received your booking.

ANY SPECIAL REQUIREMENTS:Please inform us if you have any special requirements by calling Customer Services on +44(0) 20 7017 7481.

DATA PROTECTION: The personal information shown on this form, and/orprovided by you, will be held on a database and may be shared with othercompanies in the Informa Group in the UK and internationally. If you do notwish your details to be available to other companies in the Informa Groupplease contact the Database Manager at the above address, Tel +44 (0)207017 7077, Fax +44 (0)20 7017 7828 or email: integrity@informa.com.Occasionally your details may be obtained from, or made available to, externalcompanies who wish to communicate with you offers related to your businessactivities. If you do not wish to receive these offers, please tick the box ❑

INCORRECT MAILING If you are receiving multiple mailings or you would likeus to change any details or remove your name from our database, pleasecontact the DATABASE MANAGER at the above address, Tel: +44 (0)20 70177077, Fax: +44 (0)20 7017 7828 or email: integrity@informa.com – quotingthe reference number printed on the mailing label.

Venue Details:

Georg-Glock Strasse 20, D-40474 Dusseldorf - GermanyTel: +49-211-43770 Fax: +49-211-43772519info.dusseldorf@hilton.comhttp://www1.hilton.com/en_US/hi/hotel/DUSHITW/index.do

Reduced Rate Hotel Accommodation:

The cost of the accommodation is not included in the conference fee. Reduced rateaccommodation can be obtained by going on-line tohttp://www.hilton.com/en/hi/groups/personalized/DUSHITW_GINFA/index.jhtml.

Please book early to avoid disappointment.

Conference Documentation: Cannot Attend?For those busy executives who cannot take full advantage of this event, the papers give you auseful record of the presentations made at the event. The set of speakers papers and/or slidesfrom the conference is available after the event for £299.Contact Customer Services on tel: +44(0) 20 7017 7481, fax: +44 (0) 20 7017 7823 or e-mail: registrations@informa-ls.com

�� Please invoice

�� Credit Card. Please debit my: �� �� ��

Card No:�������� �������� �������� ��������CVV No:������Expiry Date: ..................................................................................................

Signature: ..............................................................................................................

Credit card billing address:

............................................................................................................................

............................................................................................................................

Contact Number for Card Holder:

............................................................................................................................

Please note that cards will be debited within 7 days of your registration onto the conference

�� Yes I agree to the terms and conditions as stated on this form.

Delegates who do not pay with their booking are requested to provide a copy of bank transfer/ credit card / cheque details to help payment allocation. Staff at the event will request a creditcard guarantee for delegates without proof of payment.

(Mr/Mrs/Ms/Miss/Dr) Family Name zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Forename zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

E-mail zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Tel zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz Fax zxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Head of Department zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Job zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz Title zxzxzxzxzxzxzxzxzxz

Any special requirements? ..............................................................................................................................

DELEGATE DETAILS – Please photocopy form for group bookings!

Booking Contact: zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

E-mail zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Tel zxzxzxzxzxzxzxzxzxzxzxzxzxz Fax zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Name of Company zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Department zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Address zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz City zxzxzxzxzxzxzxzxzxzxzxzxzxzxz

Postcode zxzxzxzxzxzxzxzxzxzxzxzxzxzxz Country zxzxzxzxzxzxzxzxzxzxzxzxzxz

Nature of Company Business zxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxzxz

No. of employees on your site: 1) 0-49 �� 2) 50-249 �� 3) 250-499 �� 4) 500-999 5) 1000+ ��

PAYMENT INFORMATION

To assist us with future correspondence, please supply the following details:

Are we mailing you correctly? To update your contact details on our database please email integrity@informa.com

) z y

www.informa-ls.com/eurotides

*2. Select Workshops■■ X: Tools for a Start-Up Company and Site Visit ■■ Y: Nano at EuroTIDES 2008 ■■ Z: Manufacturing siRNA, aptamers and their conjugates

1. Select Event Pass Type

Book Between 5 Sept - 31 Oct 2008

❑ 1799 + VAT @19%= 2140.81

❑ 1499 + VAT @ 19% = £1783.81

❑ 1199 + VAT@ 19%= £1426.81

Book After 31 Oct 2008

❑ 1899 + VAT @ 19%= £2259.81

❑ 1599 + VAT @ 19% = 1902.81

❑ 1299 + VAT @ 19% = £1545.81

3 digit security code on the reverse of card